A B S T R A C T Using His btundle recording techniq(utes, we examined direct and auitonomically mediated condtuction system effects of (qtiinidine in five cardiac transplant recipients who have anatomically denervated hearts. We made control conduction interval and refractory period measurements, and then inftused 10 mg/kg quiinidine gltuconate over a 20-min period. At 30 min, we determined the electrophysiologic changes indtuced by quiinidine. Quiinidine significantly increased the atrial-His (AH) interval (from 97±9 [SEM] to 1083+7 ms,P < 0.001), the His-ventricular (HV) interval (from 43.9± Ito 52.8±3 ms, P < 0.01), the donor heart sintus cycle length (from 599±38 to 630 ±56 ms, P < 0.08), and the atrial effective refractory period (from 214 ± 14 to 241 ± 11 ms, P < 0.01). Qtuinidine significantly decreased the innervated, remnant atrial sintus cycle length (from 847±104 to 660±96 ms, P < 0.01) and the blood pressure. The mean plasma concentration of qutiinidine at the time that electrophysiologic measturements were repeated was 4.37+0.449 ,ug/ml. We concltude that quiinidine's predominant sintus nodal and atrioventrictular nodal effects in man are auitonomically mediated and opposite to its direct actions upon these structures. On the other hand, quinidine's prevailing effect on atrial refractoriness and His-Purkinje conduction in man is direct.
INTRODUCTION
The effect of quiinidine upon the human cardiac conduction system is controversial because quinidine has both direct and autonomically mediated electrophysiologic activities. Several investigators have attempted to identify these actions separately in animals (1) (2) (3) (4) . Studies in man, in which His bundle recordDr. Stinson is an Established Investigator of the American Heart Association.
Received for publication 7 July 1976 and in revised form 5 November 1976. ing techniquies wvere applied (5, 6), couLld not make this separation becauise of the stubjects' intact cardiac innervation wvhich permitted both actions to occur simtultaneouisly. In one of these investigations, Hirschfeld and his colleaguies (5) administered quinidine intravenously to patients with intact cardiac neural stupply and fotund a decrease in the AH interval, but no changes in the HV7 interval or the spontaneouis sintus cycle length after quinidine. Josephson et al. (6) , uising His btundle recording techniquies to study the effects of intramutsctular quiinidine in patients with intact cardiac auitonomic supply, fouind that quinidine prodtuced decreases in the sintus cycle length and the AH time, and increases in the atrial effective refractory period and His-Puirkinje condtuction time. In neither of these electrophysiologic studies in humans, however, were the direct and auitonomically mediated effects of qutinidine separately identified.
Cardiac transplant recipients provide a uiniquie model for studying the heart free of auitonomic influences (7) (8) (9) (10) (11) . In the present sttudy, we examined the effects of quiinidine administered intravenouisly to human cardiac allograft recipients to determine the drug's autonomic and direct condtuction system actions.
NIETHODS
Five cardiac allograft recipients were studied 8-20 mo after transplantation. The stuidy was approved by the Stanford Medical Committee on the Use of Human Subjects in Research, and each patient gave informed, written consent. These patients had had uncomplicated postoperative courses, and at the time of study, were in New York Heart Association Class I functional status and had no evidence of cardiac rejection or of extracardiac disease. All five patients had normal cardiac biopsies, right and left heart hemodynamic studies, and coronary and left ventricular angiograms within 6 mo of this investigation. Patients 75  80  85  80  +10  HV  45  45  50  52  +7  QT  285  370  390  390  +105  RCL  990  550  700  670  -220  DCL  640  640  645  645  +5  MBP  84  72  75  74  -12   2  480  AH  85  85  100  100  +15  HV  42  45  55  55  +13  QT  330  340  360  370  +40  RCL  1,190  1,040  1,040  1,050  -150  DCL  530  540  570  570  +40  MBP  72  79   64  66  -8   3  630  AH  110  115  115  115  +5  HV  45  50  55  60  +15  QT  325  365  415  435  +110  RCL  675  645  620  605  -70  DCL  685  700  755  740  +70  MBP  83  84  77  81  -6   4  515  AH  115  120  125  125  +10   HV  47  45  50  55  +8   QT  315  340  380  400  +85  RCL  700  620  625  520  -180  DCL  540  542  540  550  +10  MBP  113  110  97  98  -15   5  670  AH  100  105  115  115  +15  HV  40  40  42  40  +2  QT  335  460  475  475  +140  RCL  680  650  590  585  -95   DCL   MBP  105  103  95  96  -9 * Electrophysiological intervals in ms, blood pressure in millimeters of mercury. vals were recorded at the spontaneous and the base paced heart rate. The atrial effective refractory period and the refractory periods of the atrioventricular node were determined using the extra-stimulus technique (12) . After every eighth paced beat (S,), a premature stimulus (S2) was introdtuced. The S1-S2 interval was then reduced by 10-msdecrements until the effective refractory period of the atrium was reached. The atrial effective refractory period was defined as the longest S1-S2 interval at which S2 failed to depolarize the atrium. defined as the shortest H1-H2 interval achieved, and the AV nodal effective refractory period was defined as the longest A1-A2 at which A2 failed to conduct through the AV node to produce a His bundle potential. The spontaneous donor and recipient atrial cycle lengths were recorded as the average, to the nearest 5 ms, of 15 sequential atrial cycles at each data interval. Central aortic blood pressure was measured through a PE 160 catheter placed transfemorally and connected to a Statham P23DB transducer (Statham Instruments Div., Gould Inc., Oxnard, Calif.)
After control measurements, quinidine gluconate salt, in a solution of 16 mg/cm3 of 5% dextrose and water, was administered to a total dose of 10 mg/kg by constant intravenous infusion over 20 min. The AH, HV, and QT intervals, the sinus cycle lengths, and the blood pressure were then remeasured during spontaneous sinus rhythm and during pacing at the previously selected base pacing cycle length at 5, 15, and 25 min after initiation of the infusion. Repeat sinus node recovery times and refractory studies of the AV conduction system were accomplished at 30 min after the initiation of the infusion. Blood samples were obtained for plasma quinidine determinations before, and at 5, 15, 25, 30, and 40 min after the start of drug administration. Quinidine was assayed by the benzene-extraction technique (13) .
To confirm persistence of functional cardiac denervation, the day before this investigation all five subjects had shown a delayed heart rate response, in onset and offset, to treadmill exercise testing, and after the study showed absence ofa rate response to 1 mg atropine administered intravenously.
Differences between electrophysiologic measurements recorded before and after quinidine administration were analyzed by the two-tailed Student's t test for paired data.
RESULTS
Conduction intervals. Table I and Fig. 1 show quinidine's effects upon cardiac conduction intervals during base-rate atrial pacing. In general, maximum changes in the AH, HV, and QT intervals were observed at 15 min of infusion, by which time they had reached a plateau. Maximum changes in these intervals are illustrated in Fig. 2 . Despite the small number of patients, the postquinidine mean values were significantly different from control measurements. The AH interval increased in all five patients from 97+8 to 108+7 (SEM) ms (P <0.001). The HV interval was lengthened in all subjects from a mean of 43.8+1 to 52.8±3 ms (P s 0.01). The QT interval also increased in all five patients from a mean of 318±9 to 414±19 ms (P < 0.005).
Effect on sinus nodes. At transplantation, the posterior walls of the recipient atria, with the sinus node intact, are left in place for attachment of the donor atria. Thus, both the recipient and the donor sinus nodes remain functional after transplantation. The implanted donor sinus node is denervated, while the remnant recipient node retains its neural innervation. Separate donor and recipient atrial depolarizations can be detected by surface and intracardiac electrocardiography (14) . Effect of atrial and AV nodal refractory periods. The atrial effective refractory period increased in all five patients from a mean value of 214+ 14 to 241+ 11 ms (P < 0.01) (Fig. 5) . The AV nodal ftunctional refractory period was variably affected; it increased in three of the patients, remained unchanged in one, and decreased in the fifth patient (Table III) periods of the His-Purkinje system could not be determined in any of the patients, due to earlier refractoriness higher in the conduction system. Effect on blood pressure. Sequential changes in mean blood pressure are recorded in Table I . The average mean central aortic blood pressure fell from 91.4+±7.6 to 81.0+6.5 (P < 0.005) at its nadir after quinidine administration.
Plasma quinidine concentrations. Mean plasma quinidine levels at 5, 15, 25, 30, and 40 min after initiation of the infusion were 2.36, 9.83, 6.12, 4.37, and 3.95 ,ug/ml, respectively. Although a true steadystate condition was not achieved at the time that the repeat refractory determinations and sinus node recovery measurements were made, the plasma quinidine concentrations had almost reached a plateau and the mean concentration of 4.37±0.449 (SEM) ,ug/ml (range 3.07-5.14 ,ug/ml) is similar to the 4.6 ,g/ml level reported by Josephson et al. (6) after intramuscular injections, and is within the range considered therapeutic for chronic oral therapy. One patient experienced a brief episode of nausea, but no other patient reported subjective side effects. Ventricular irritability was not encountered during or after the study, as determined by continuous electrocardiographic monitoring.
DISCUSSION
We have studied the denervated hearts of five cardiac transplant recipients to identify direct electrophysiologic effects of quinidine upon the human cardiac conduction system. Transplant recipients provide a model for the study of cardiac drug actions in a millieu free of direct autonomic nervous influences.
To support the contention that functional autonomic denervation persists in long-term human cardiac transplant survivors, we have shown that the present subjects', and other cardiac recipients', rate responses to exercise are sluggish, both in onset and offset, as is observed in animals with anatomic cardiac denervation (15) . Furthermore, those long-term survivors who have suffered myocardial infarctions have not experienced cardiac pain. Finally, pharmacologic interventions with intravenous atropine and tyramine, and inhaled amyl nitrite, which result in tachycardia in subjects with normal cardiac innervation, produce no significant heart rate changes in transplant recipients (7, 15) .
Studies of direct electrophysiologic effects in isolated tissue have shown that quinidine alters action potentials of the cells of the cardiac conduction system. Slowing of phase zero (upstroke) and delays of phase two (plateau) and phase three (rapid repolarization) of the action potential are seen (16 (6) . The quinidine levels which Josephson et al. recorded in their electrophysiologic stuLdy are similar to the concentrations which we attained. We make a more detailed comparison of our findings in cardiac transplant recipients with their findings in intact humans below (Table IV) .
The innervated sinus node of the recipient's excised heart remains present and intact, and serves as a "control" for comparison with the denervated donor sinus node. This innervated node significantly increased its rate of depolarization after quinidine administration (Fig. 3A) which is consistent with the findings of Josephson et al. of an increased heart rate after intramuscular quinidine adIministration. On the other hand, the denervated donor sinus rate was slowed by quinidine in all four patients in whom sinus rate could be measured (Fig. 3B) . Although this change fell short of statistical significance, (P < 0.08), the consistency of the response holds greater weight than statistical analysis in such a small sample. This comparison of the two sinus nodes within the same patient clearly separates quinidine's direct effect, which is to depress sinus node autonomaticity, from its autonomically mediated acceleratory effect on the sinus node. James and Nadeau (4) concluded, from their direct sinus node perfusion studies in the anes- However, factors other than automiiaticity affect the postpacing recovery times, such as perinodal entraince and exit block (19, 20) , local metabolic factors (21, 22) , and fiber stretch (22) . Because the mean blood pressure fell by approximately 10 mm Hg in this group of subjects, the possibility of a resultant reflex sympathetically mediated acceleration of the innervated recipient sinus rate (rather than a vagolytic quinidine effect) caninot be entirely dismissed. However, the occurrence of recipient atrial acceleration in the absence of a significant fall, and even in the presence of a rise, in blood pressure at several data points (Table I, Our transplant recipients and Josephson and colleagues' normal patients showed similar changes in His-Purkinje conduction time after quinidine administration. Prolongation of the HV interval by quinidine, then, appears to be a direct effect, as it occurs in the absence of autonomic innervation. The possibility still exists that additional autonomic effects of quinidine might influence the human HisPurkinje system, which has sympathetic and histologically demonstrated cholinergic innervation (23) . However, since our subjects showed HV interval changes of a magnitude similar to those of patients with intact autonomic innervation, it would appear that the major portion of quinidine's effect upon the HisPurkinje system is direct.
The magnitude of increase in the atrial effective refractory period after quinidine in transplant recipients ( Fig. 5) was similar to that which occurs in normally innervated patients. This finding documents the existence of a direct drug effect upon the atrium of man. Quinidine's anticholinergic activity should also prolong refractoriness of atrial tissue. Although both mechanisms probably act in concert in intact man, a similarity in the degree of change in innervated and denervated hearts favors a predominance of the direct effect.
We have drawn four conclusions regarding the cardiac conduction system actions of quinidine in man. These conclusions are supported by previous animal investigations, and represent the first clear separation of quinidine's direct activity and its autonomically mediated activity in man. First, the enhancement of sinus rate seen after quinidine administration in man is a neurally mediated effect, dependent upon an intact cardiac autonomic supply; quinidine's direct effect is to slow the rate of depolarization of the sinus node. Second, the net enhancement of AV nodal conduction by quinidine in man is most likely due to an autonomic effect which opposes and outweighs its direct slowing effect upon the AV node. Third, quinidine decreases His-Purkinje conduction by a direct action which can occur independently of autonomic influences. Fourth, the cardiac autonomic nervous system is not critically involved in quinidine's prolongation of the atrial refractory period.
